Latest Als News

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Tivan Limited has visually confirmed copper mineralisation at two sites within its Turiscai Project in Timor-Leste, setting the stage for assay results later this year and resource drilling in 2026.

Haranga Resources’ due diligence sampling at the Lincoln Gold Project confirms robust, high-grade gold assays, underpinning confidence in upcoming drilling and resource estimates. The historic data integrity and assay consistency pave the way for the Phase 1 diamond drill program planned for August 2025.

Golden Cross Resources has completed an extensive surface geochemistry sampling program at its Copper Hill project in NSW, revealing isolated copper and gold anomalies that refine exploration targets.

Lightning Minerals has initiated site preparations for a Phase 1 drilling campaign at the Mt Turner Gold Project in Queensland, aiming to unlock deeper gold mineralisation beneath historic pits. The move follows a recent funding boost and is part of the company’s proposed acquisition of Lotus Minerals.

New Frontier Minerals reports strong copper recovery from historical stockpiles at its Big One Deposit, supporting a fast-tracked production pathway through Austral Resources’ Mt Kelly facility.

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Lode Resources has reported impressive high-grade antimony and silver intercepts from its ongoing drilling program at the Montezuma Project in Tasmania, revealing new lodes and extending mineralisation.

Adavale Resources has launched its first-ever drilling campaign at the London Victoria Gold Mine, aiming to expand its existing gold resource and explore high-grade vein potential near the historic Koh-I-Nor mine.

ALS Limited reported a robust FY25 with 16% revenue growth to AUD 3 billion, underpinned by strong organic expansion and key acquisitions. Despite slight NPAT decline, the company advances its sustainability agenda and invests in global lab upgrades.

Solis Minerals has intersected promising copper-gold mineralisation including visible gold at its Chancho al Palo prospect in Peru, with assays expected in July/August 2025. The initial drill hole confirms the presence of both IOCG and porphyry-style systems in a highly prospective region.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.